Cheryl Waters

10.2k total citations
107 papers, 5.0k citations indexed

About

Cheryl Waters is a scholar working on Neurology, Physiology and Cognitive Neuroscience. According to data from OpenAlex, Cheryl Waters has authored 107 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Neurology, 20 papers in Physiology and 16 papers in Cognitive Neuroscience. Recurrent topics in Cheryl Waters's work include Parkinson's Disease Mechanisms and Treatments (83 papers), Neurological disorders and treatments (41 papers) and Botulinum Toxin and Related Neurological Disorders (15 papers). Cheryl Waters is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (83 papers), Neurological disorders and treatments (41 papers) and Botulinum Toxin and Related Neurological Disorders (15 papers). Cheryl Waters collaborates with scholars based in United States, Canada and France. Cheryl Waters's co-authors include Stanley Fahn, Karen Marder, Melissa J. Nirenberg, Mark Lew, Elan D. Louis, Steven J. Frucht, Howard Andrews, Helen Mejia‐Santana, Juliette Harris and Blair Ford and has published in prestigious journals such as PLoS ONE, Brain and Neurology.

In The Last Decade

Cheryl Waters

104 papers receiving 4.8k citations

Peers

Countries citing papers authored by Cheryl Waters

Since Specialization

Citations

This map shows the geographic impact of Cheryl Waters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cheryl Waters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cheryl Waters more than expected).

Fields of papers citing papers by Cheryl Waters

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cheryl Waters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cheryl Waters. The network helps show where Cheryl Waters may publish in the future.

Co-authorship network of co-authors of Cheryl Waters

This figure shows the co-authorship network connecting the top 25 collaborators of Cheryl Waters. A scholar is included among the top collaborators of Cheryl Waters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cheryl Waters. Cheryl Waters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Are rare heterozygous SYNJ1 variants associated with Parkinson’s disease? 2024 ·npj Parkinson s Disease ·Konstantin Senkevich, (unknown), (unknown), Eric Yu, Jamil Ahmad, Jennifer A. Ruskey, Farnaz Asayesh, (unknown), Cheryl Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupré, Irina Miliukhina, (unknown), Anton Emelyanov, Sofya Pchelina, Lior Greenbaum, Sharon Hassin‐Baer, Roy N. Alcalay, Ziv Gan‐Or	0
2	Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease 2021 ·Movement Disorders ·Matthew Surface, Manisha Balwani, Cheryl Waters, (unknown), Ziv Gan‐Or, Karen Marder, (unknown), (unknown), Shalini Padmanabhan, F. Hsieh, Kalpana Merchant, Roy N. Alcalay	28
3	LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease 2021 ·Neurobiology of Aging ·(unknown), Eric Yu, Lynne Krohn, Uladzislau Rudakou, Kheireddin Mufti, Jennifer A. Ruskey, Farnaz Asayesh, Sandra B. Laurent, Dan Spiegelman, Stanley Fahn, Cheryl Waters, S. Pablo Sardi, Sara Bandrés‐Ciga, Roy N. Alcalay, Ziv Gan‐Or, Konstantin Senkevich	15
4	Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other associations 2020 ·Brain ·Uladzislau Rudakou, Eric Yu, Lynne Krohn, Jennifer A. Ruskey, Farnaz Asayesh, Yves Dauvilliers, Dan Spiegelman, Lior Greenbaum, Stanley Fahn, Cheryl Waters, Nicolas Dupré, Guy A. Rouleau, Sharon Hassin‐Baer, Edward A. Fon, Roy N. Alcalay, Ziv Gan‐Or	29
5	Analysis of Heterozygous PRKN Variants and Copy‐Number Variations in Parkinson's Disease 2020 ·Movement Disorders ·Eric Yu, Uladzislau Rudakou, Lynne Krohn, Kheireddin Mufti, Jennifer A. Ruskey, Farnaz Asayesh, Mehrdad A. Estiar, Dan Spiegelman, Matthew Surface, Stanley Fahn, Cheryl Waters, Lior Greenbaum, Alberto J. Espay, Yves Dauvilliers, Nicolas Dupré, Guy A. Rouleau, Sharon Hassin‐Baer, Edward A. Fon, Roy N. Alcalay, Ziv Gan‐Or	29
6	Association study of DNAJC13, UCHL1, HTRA2, GIGYF2, and EIF4G1 with Parkinson's disease 2020 ·Neurobiology of Aging ·Prabhjyot Saini, Uladzislau Rudakou, Eric Yu, Jennifer A. Ruskey, Farnaz Asayesh, Sandra B. Laurent, Dan Spiegelman, Stanley Fahn, Cheryl Waters, Oury Monchi, Yves Dauvilliers, Nicolas Dupré, Lior Greenbaum, Sharon Hassin‐Baer, Alberto J. Espay, Guy A. Rouleau, Roy N. Alcalay, Edward A. Fon, Ronald B. Postuma, Ziv Gan‐Or	25
7	A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease 2020 ·Parkinsonism & Related Disorders ·Eric S. Farbman, Cheryl Waters, Peter A. LeWitt, Monika Rudzińska, (unknown), Amanda Lee, Jenny Qian, Charles Oh, Robert A. Hauser	15
8	Safety, tolerability and pharmacokinetics of oral venglustat in Parkinson’s disease patients with a GBA mutation (S4.002) 2019 ·Neurology ·Tanya Fischer, Thomas Gasser, Stuart Isaacson, Jaime Kulisevsky, Pablo Mir, Tanya Simuni, Anne‐Marie Wills, Leonor Correia Guedes, Per Svenningsson, Cheryl Waters, Allena Ji, Jian Li, (unknown), (unknown), S. Pablo Sardi, Stéphane Saubadu, Jyoti Sharma, Michel Peterschmitt	3
9	Efficacy results of a 12-month, dose-level blinded study of CVT-301 (levodopa inhalation powder) in patients with Parkinson’s disease (P2.8-048) 2019 ·Neurology ·Eric S. Farbman, Mark Lew, Cheryl Waters, Robert A. Hauser, (unknown), Charles Oh	1
10	Common and rare GCH1 variants are associated with Parkinson's disease 2018 ·Neurobiology of Aging ·Uladzislau Rudakou, Bouchra Ouled Amar Bencheikh, Jennifer A. Ruskey, Lynne Krohn, Sandra B. Laurent, Dan Spiegelman, Christopher Liong, Stanley Fahn, Cheryl Waters, Oury Monchi, Edward A. Fon, Yves Dauvilliers, Roy N. Alcalay, Nicolas Dupré, Ziv Gan‐Or	17
11	The Development of the Rotigotine Transdermal Patch 2013 ·Neurologic Clinics ·Cheryl Waters	26
12	Zydis selegiline in the management of Parkinson's disease 2007 ·Expert Opinion on Pharmacotherapy ·Kathleen L. Poston, Cheryl Waters	8
13	Familial aggregation of early‐ and late‐onset Parkinson's disease 2003 ·Annals of Neurology ·Karen Marder, Gilberto Levy, Elan D. Louis, Helen Mejia‐Santana, Lucien Côté, Howard Andrews, Juliette Harris, Cheryl Waters, Blair Ford, Steven J. Frucht, Stanley Fahn, Ruth Ottman	70
14	Treatment of advanced stage patients with Parkinson's disease 2002 ·Parkinsonism & Related Disorders ·Cheryl Waters	13
15	The long-term safety and efficacy of pramipexole in advanced Parkinson's disease 2001 ·Parkinsonism & Related Disorders ·William J. Weiner, Stewart A. Factor, Joseph Jankovic, Robert A. Hauser, James W. Tetrud, Cheryl Waters, Lisa M. Shulman, (unknown), (unknown), (unknown), (unknown)	29
16	Tolcapone Improves Motor Function and Reduces Levodopa Requirement in Patients with Parkinson's Disease Experiencing Motor Fluctuations 1997 ·Neurology ·Matthias Kurth, Charles H. Adler, Melissa St Hilaire, Carlos Singer, Cheryl Waters, P. LeWitt, DORIS A. CHERNIK, Ernest Dorflinger, Kisook Yoo	151
17	Fluoxetine and Selegiline – Lack of Significant Interaction 1994 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Cheryl Waters	29
18	Effects of Selegiline Dosing on Motor Fluctuations in Parkinsonʼs Disease 1993 ·Clinical Neuropharmacology ·Jean Hubble, William C. Koller, Cheryl Waters	19
19	Chapter 77 Stereotactic adrenostriatal autografts for parkinsonism: rationale, techniques and observations 1990 ·Progress in brain research ·John H. Neal, Michael L.J. Apuzzo, Cheryl Waters	3
20	Cognitive Enhancing Agents: Current Status in the Treatment of Alzheimer's Disease 1988 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Cheryl Waters	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact